Algernon Health Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare company, is pleased to announce a non-brokered private placement for gross ...

Planned U.S. launch of Anaphylm™ in the first quarter of 2026, if approved by the FDA Advanced Anaphylm regulatory activities in Canada and the ...

Q3 2025 Earnings Call Transcript November 4, 2025 Harmony Biosciences Holdings, Inc. misses on earnings expectations.

There is a bidirectional association between myocardial infarction (MI) and late-onset epilepsy (LOE), according to a study published online Nov. 5 in Neurology.

Translation factors eIF1A and eIF5B are key repressors of an abnormal protein translation process linked to neurodegenerative ...

Jazz Pharmaceuticals plc today announced financial results for the third quarter of 2025 and updated financial guidance for 2025. "Achieving the highest revenue quarter in Jazz's history speaks to the ...